Genentech @genentech · 15 Jul 2026
#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more: https://t.co/oABNpP4zxh
2 660Views
10Likes
4Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
1.00×vs this author's median2 660 views is typical
40Percentile for this authorof 5 recent posts
0.12×vs 100K–1M median21 891 views is typical
2.16%Reachviews ÷ followers
0.53%Engagement rateof viewers reacted